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A B S T R A C T
Arsenic is a common environmental contaminant from both naturally-occurring and anthropomorphic sources
and human exposure can be detected in various tissues. Its toxicity depends on many factors including the
chemical form, valence state, bioavailability, metabolism and detoxiﬁcation within the human body. Of
paramount concern, particularly with respect to health eﬀects in children, is the timing of exposure as the
prenatal and early life periods are more susceptible to toxic eﬀects. The Maternal-Infant Research on
Environmental Chemicals (MIREC) cohort was established to obtain national-level biomonitoring data for
approximately 2,000 pregnant women and their infants between 2008 and 2011 from 10 Canadian cities. We
measured total arsenic (As) in 1st and 3rd trimester maternal blood, umbilical cord blood, and infant meconium
and speciated arsenic in 1st trimester maternal urine. Most pregnant women had detectable levels of total
arsenic in blood (92.5% and 87.3%, respectively, for 1st and 3rd trimester); median diﬀerence between 1st and
3rd trimester was 0.1124 µg/L (p <0.0001), but paired samples were moderately correlated (Spearman r=0.41,
p <0.0001). Most samples were below the LOD for umbilical cord blood (50.9%) and meconium (93.9%). In 1st
trimester urine samples, a high percentage ( >50%) of arsenic species (arsenous acid (As-III), arsenic acid (As-
V), monomethylarsonic acid (MMA), and arsenobetaine (AsB)) were also below the limit of detection, except
dimethylarsinic acid (DMA). DMA ( >85% detected) ranged from <LOD to 64.42 (95th percentile: 11.99)
µg As/L. There was a weak but signiﬁcant correlation between total arsenic in blood and speciﬁc gravity-
adjusted DMA in urine (Spearman r=0.33, p <0.0001). Among this population of pregnant woman and
newborns, levels of arsenic measured in blood and urine were lower than national population ﬁgures for
Canadian women of reproductive age (20–39 years). In general, higher arsenic levels were observed in women
who were older, foreign-born (predominantly from Asian countries), and had higher education. Further
research is needed to elucidate sources of exposure and factors that may inﬂuence arsenic exposure in pregnant
women and children.
1. Introduction
Arsenic (As) is a ubiquitous metalloid that is present in the
environment from both naturally-occurring and anthropomorphic
sources. Environmental contamination is a worldwide concern result-
ing in human exposure to both inorganic and organic forms. Human
exposure generally occurs from the consumption of inorganic arsenic in
drinking water and diet (National Research Council [NRC] 2013).
Organic arsenic is formed through biological reactions with inorganic
arsenic in aquatic environments resulting in human exposure to
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organic arsenicals mainly from seafood. Arsenic toxicity depends on
many factors including its chemical form, valence state, bioavailability,
metabolism and detoxiﬁcation within the human body (National
Research Council (NRC), 2013; Vahter and Concha, 2001).
The complex chemistry and toxicokinetics of arsenic aﬀect the
availability and choice of exposure biomarkers. Measurements of total
arsenic in human tissues represent the sum of both the inorganic and
organic species. Laboratory analytical advances and availability of a
standard reference material containing both inorganic and organic
arsenic species allows for more complex speciated arsenic measure-
ments (Le et al., 2000; Xie et al., 2006).
Although the toxicity and health eﬀects of arsenic species are still
being elucidated, some of the methylated metabolites of inorganic
arsenic are thought to be the most toxic to humans (Cohen et al., 2006).
Once ingested, greater than 90% of inorganic arsenic (As) is absorbed
by the gastrointestinal tract with As5+ reduced to As3+ in blood and
metabolized by the liver to monomethylarsonic acid (MMA-V). This, in
turn, is reduced to the highly reactive/highly toxic monomethylarsinic
acid (MMA-III) which is methylated again to dimethylarsinic acid
(DMA) and excreted in urine within a few hours (National Research
Council (NRC), 2013; Watanabe and Hirano, 2013). The organoarse-
nicals, primarily arsenobetaine and arsenocholine, are generally
thought to be absorbed and excreted untransformed, thus considered
non-toxic. Correlations have been reported between ﬁsh and shellﬁsh
consumption and urinary concentrations of arsenobetaine (Lovreglio
et al., 2012; Rivera-Núñez et al., 2012). However, research now
suggests that arsenobetaine may also be formed endogenously in
humans (Molin et al., 2015). One study has suggested that arsenobe-
taine is a human metabolite of DMA or inorganic arsenic from food, or
both (Newcombe et al., 2010).
The International Agency for Research on Cancer (IARC) classiﬁes
inorganic arsenic as a group-1 human carcinogen and associations have
been found with lung, bladder, skin, kidney, liver and prostate cancer
(IARC (International Agency for Research on Cancer), 2012). A range
of non-carcinogenic eﬀects, including cardiovascular disease (Tsuji
et al., 2014), hypertension (Abhyankar et al., 2012), and diabetes
(Wang et al., 2014), have also been observed. Low-level environmental
exposure has been associated with impaired glucose tolerance during
pregnancy (Ettinger et al., 2009; Shapiro et al., 2015). Arsenic is known
to cross the placenta and prenatal exposure is associated with adverse
birth and developmental outcomes (National Research Council (NRC),
2013; Vahter, 2009).
Human and experimental studies have shown that the susceptibility
of the developing embryo/fetus to environmental factors is dependent
on the timing of exposures during critical windows of prenatal
development (Selevan et al., 2000). Canada's Maternal-Infant
Research on Environmental Chemicals (MIREC) cohort was estab-
lished to obtain national biomonitoring data for pregnant women and
their infants and to examine potential adverse health eﬀects of prenatal
exposure to priority environmental chemicals (Arbuckle et al., 2013).
Previous analyses of associations between maternal blood As levels and
health outcomes in the MIREC Study have reported no signiﬁcant
associations with small for gestational age births (Thomas et al., 2015),
fetal markers of metabolic function (Ashley-Martin et al., 2015a) or
immune function (Ashley-Martin et al., 2015b), or impaired glucose
tolerance during pregnancy (Shapiro et al., 2015). However, maternal
blood As was signiﬁcantly associated with gestational diabetes (Shapiro
et al., 2015) and urinary arsenobetaine levels were associated with a
higher risk of small for gestational age births (Thomas et al., 2015).
MIREC has one of the richest sources of information to date on
prenatal exposure biomarkers including measurements in maternal
blood, urine, breast milk, and neonatal umbilical cord blood and
meconium from nearly 2,000 mother-newborn pairs. Here, we present
the MIREC arsenic exposure biomarker data for total arsenic in 1st and
3rd trimester maternal blood, umbilical cord blood, and infant
meconium and speciated arsenic in 1st trimester maternal urine and
examine diﬀerences in arsenic concentrations by selected maternal
characteristics.
2. Materials and methods
2.1. Study population
MIREC enrolled 2,001 women in the ﬁrst trimester of pregnancy
between 2008 and 2011 from 10 cities in six Canadian provinces:
Vancouver, Edmonton, Winnipeg, Sudbury, Ottawa, Kingston,
Hamilton, Toronto, Montreal and Halifax. The study was reviewed
and approved by the Research Ethics Board of Health Canada as well as
the ethics committees at each of the 10 participating clinical study sites
and collaborating institutions. Details on the cohort have been
published previously (Arbuckle et al., 2013).
Brieﬂy, women at least 18 years of age or older with English or
French language ability, willing to provide a cord blood sample, and
intending to deliver at a local hospital, were recruited between six and
13 weeks of pregnancy ( <14 weeks gestation) and followed through
pregnancy and up to ten weeks after a pregnancy (for breast milk
collection). Women with histories of medical complications or known
fetal abnormalities or chromosomal or major malformations in the
current pregnancy, or those with a major chronic illness, threatened
abortion, or illicit drug use were excluded. Biological samples of
maternal blood and urine were collected at each trimester of pregnancy
and at delivery, neonatal umbilical cord blood at delivery and meco-
nium within the ﬁrst few days after delivery. Extensive information was
collected by interviewer-administered questionnaires and medical
chart review on a number of variables, including: socio-demographic
characteristics; maternal anthropometry; obstetrical history; and
smoking. After data collection, 18 women asked to withdraw from
the study and their data and biospecimens were destroyed. Additional
loss to follow-up over the course of the pregnancy was due to:
withdrawals from the study (N=48), fetal demise (N=41), therapeutic
abortion (N=13), mobility of the participants outside the study site
(N=14) or the biospecimen was not collected.
2.2. Laboratory methods
Blood was collected in 6-mL K2 EDTA tubes at the 1st and 3rd
trimester visits using standard phlebotomy procedures. Umbilical cord
blood was collected at delivery using a S-Monovette® (Sarstedt,
Germany), and meconium was collected within the ﬁrst two days after
delivery using a Mère Hélène® bioliner (Mère Hélène, Quebec, Canada)
inserted in the diaper. All whole blood and meconium samples were
aliquotted and stored in Sarstedt® tubes. First trimester (median
gestational age 12.4, range 6.1–14.9 weeks) urine samples were
collected in 125-mL Nalgene® containers (Thermo-Fisher Scientiﬁc
Inc., Rochester NY, USA), aliquoted into 30-mL Nalgene® containers,
frozen at −20 °C within 2 h of collection and shipped on dry ice to the
MIREC coordinating center in Montreal where they were stored at
−30 °C. Potential contamination of the collection materials was
assessed by pre-screening for trace metals. Field blanks using water
(Steril.O reagent grade deionized distilled water) were collected and
tested to assess for possible contamination during the collection,
processing, transportation and storage procedures.
Samples were shipped in batches for analysis to the Centre de
Toxicologie du Québec, Institut national de Santé Publique du Québec
(INSPQ) (http://www.inspq.qc.ca/ctq/), which is accredited by the
Standards Council of Canada under ISO 17025 and CAN-P-43. The
accuracy and precision of the analyses are evaluated on a regular basis
through the laboratory's participation in external quality assessment
programs. Samples were received at the laboratory, registered into the
laboratory information management system, and stored at −20 °C until
analysis. On the day before analysis, samples are placed at 4 °C to be
thawed if necessary. Sample preparation and analysis were carried out
A.S. Ettinger et al. Environmental Research 153 (2017) 8–16
9
in a laboratory that was speciﬁcally designed and dedicated to trace
element analysis.
Blood (500 µL) and cord blood (250 µL) samples were diluted, 20-
fold, 40-fold, or 50-fold in a diluent containing 0.5% (v/v) NH4OH and
0.1% (v/v) octylphenol ethoxylate. The samples diluted 1/20, 1/40, or
1/50 have corresponding limits of detection (LOD), respectively, of:
0.225 μg/L (3.0 nmol/L), 0.449 μg/L (6 nmol/L), or 0.599 μg/L
(8 nmol/L). External calibration curves were prepared by diluting the
corresponding volume of human blood (from healthy volunteers) with
diluent and then spiking with diﬀerent volumes of 1 mg/L multi-
elements standard solution (SCP Science, PlasmaCal ICP-MS
Veriﬁcation Standard 1; 5% HNO3, #141-110-011). The internal
standards for the calibration curve and the blood samples analysis
were 89Y (for 75As). Internal quality assurance was ensured by running
validated reference materials (QMEQAS08B05, QMEQAS08B08, QM-
B-Q1108 and QM-B-Q1201: human blood from the Quebec Multi-
element External Quality Assessment Scheme (QMEQAS) inter-labora-
tory comparison scheme) after calibration, after every 10th sample as
well as at the end of each analytical sequence.
Meconium was thawed and homogenized and a sample (500 mg)
was predigested at room temperature in a Teﬂon bomb for three hours
under acidic conditions (2 mL HNO3). The bombs were then sealed and
placed at 110 °C for 18 h to complete the digestion. The digest was
diluted 50-fold with an aqueous solution (diluent) containing 0.002%
(m/v) L-(+)-cystein and 100 µg/L Au. External calibration curves were
prepared in 2% (v/v) HNO3 containing 0.002% (m/v) L-(+)-cystein and
100 µg/L Au by spiking with diﬀerent volumes of 1 mg/L multi-
elements standard solution (SCP Science, PlasmaCal ICP-MS
Veriﬁcation Standard 1; 5% HNO3, #141-110-011). The internal
standards for calibration standards and meconium samples were 89Y
(for 75As). Internal quality assurance was ensured by running standard
reference materials (SRM 1577b: bovine liver from the National
Institute of Standards and Technology (NIST) Gaithersburg, MD
USA) and validated reference materials (QM-H-Q1101: human hair
from the Quebec QMEQAS external quality assessment scheme) after
calibration, after every 10th sample and at the end of each analytical
sequence.
Blood, cord blood, and meconium were analyzed using a single-
quadrupole inductively coupled plasma mass spectrometry (ICP-MS)
Elan DRC-II system (Perkin Elmer, Norwalk CT, USA). Limits of
detection (LOD) for blood and meconium, respectively, were: 0.225 µg/
L and 0.02 µg/g.
Urine (100 µL) was diluted 1/10 with solvent of elution then
injected on instrument with no prior sample preparation steps.
Arsenic species (arsenite (As-III), arsenate (As-V), dimethylarsinic acid
(DMA), monomethylarsonic acid (MMA), arsenobetaine (AsB)) were
measured by HPLC coupled with ICP-MS (Varian 820-MS, Varian Inc.,
Palo Alto CA, USA) with limits of detection (LOD) equal to 0.75 µg As/
L (0.01 µmol/L) according to the method of Bélanger and Dumas
(2010). Speciﬁc gravity was measured in thawed urine samples by
refractometry (UG-1, Atago # 3461, Atago U.S.A. Inc., Bellevue WA,
USA) to control for urine dilution.
2.3. Statistical analysis
Descriptive statistics, including sample size, detection limit, per-
centage of observations below the limit of detection (LOD), minimum,
median, 95th percentile, maximum, geometric mean, and associated
95% conﬁdence interval were calculated for arsenic biomarkers.
Spearman correlation coeﬃcients were calculated between biomarkers
when at least 50% of the data were above the LOD.
Due to the non-normality of the data, the Wilcoxon signed rank test
or sign test was used to test whether the medians of the 1st and 3rd
trimester blood measurements were equal. Arsenic values below the
LOD were deﬁned as left-censored and methods to account for left-
censoring were implemented.
The geometric mean from a lognormal random variable with
censoring was calculated using the parametric maximum likelihood
(ML) method and compared to the empirical median from the
nonparametric Kaplan-Meier (KM) approach (Helsel, 2012; Nysen
et al., 2012). The Greenwood estimate of variance was used for
determination of Kaplan-Meier conﬁdence intervals. The parametric
and nonparametric censoring methods were used only for biomarkers
with at least 50% of the data above the LOD. Justiﬁcation for including
contaminants with up to 50% censoring is provided in Helsel (2012).
Maternal characteristics considered in the analysis included: age
group ( <25, 25–29, 30–34, ≥35 years); parity (0, 1, ≥2); pre-
pregnancy body mass index (BMI <25, 25≥BMI <30, BMI≥30); smok-
ing status (current or quit during pregnancy, former, never); Canadian-
born (yes, no) and region of birth; household income (≤$50K, >$50K–
100K, >$100K); education level (high school, some college/college
diploma, university degree); season of sample collection (fall, winter,
spring, summer); fasting status (yes, no); and, for urine only, time of
sample collection (6:00–9:00, 9:00–12:00, 12:00–15:00, 15:00–18:00,
18:00–24:00) and time since last urination (≤75, 76–120, 121–170,
>170 min). Infant sex, maternal smoking status and season of sample
collection were considered for cord blood and meconium. Summary
statistics were reported for each variable group and statistical hypoth-
esis testing was used to test for signiﬁcant diﬀerences among the
groups.
Urine concentrations in 1st trimester samples are presented both
unadjusted and adjusted by urine speciﬁc gravity (SG) using the
following formula (adapted from Just et al., 2010):
P P SG
SG
= − 1
− 1c i
m
i
⎡
⎣⎢
⎤
⎦⎥
where Pc is the SG-adjusted metabolite concentration, Pi is the
observed metabolite concentration, SGi is the speciﬁc gravity of the
ith urine sample and SGm is the median SG for the cohort. One urine
sample was excluded from the analysis because it was deemed too
dilute (speciﬁc gravity =1.000, equivalent to water) and all chemical
results were below the limits of detection. Three samples for which no
speciﬁc gravity results were available were included in the unadjusted
analyses, but excluded from adjusted analyses.
For blood arsenic, maximum likelihood estimation was employed to
account for left–censored repeated measures (Jin et al., 2011)and
hypothesis testing was performed using the data from both the 1st and
3rd trimesters, by means of likelihood ratio tests which follow a chi-
square distribution. These methods were implemented where at least
50% of the observations were above the LOD. Conﬁdence intervals
were computed for geometric mean contaminant levels by demographic
variables of interest, correcting for multiple pairwise comparisons
(Bonferonni-adjusted) using Empirical Bayes estimates of the random
eﬀects (McCulloch et al., 2008). Hypothesis testing was performed to
determine if there were signiﬁcant diﬀerences in urinary arsenic levels
by maternal characteristics with speciﬁc gravity treated as a covariate.
Statistical analysis was performed using SAS (Statistical Analysis
System) Enterprise Guide 4.2 (SAS Institute, Cary NC, USA) and R (R
Core Development Team) for analysis. For the censoring methods,
functions from the R packages NADA and SURVIVAL and SAS
procedure NLMIXED were used for analysis. Unless otherwise indi-
cated, a 5% signiﬁcance level (α=0.05) was implemented throughout.
3. Results
Table 1 shows descriptive statistics for total As in maternal blood,
umbilical cord blood and meconium. Most pregnant women had
detectable levels of arsenic in blood (92.5% and 87.3% greater than
the LOD, respectively, for 1st and 3rd trimester samples); however,
most samples were below the LOD for cord blood (50.9%) and
especially meconium (93.9%). Concentrations of blood As in the 1st
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trimester of each woman tended to be higher than her paired sample
from the 3rd trimester, with the median of the diﬀerences between 1st
and 3rd trimester As in blood of 0.11 µg/L (p <0.0001); however, the
paired samples were only modestly correlated (Spearman r=0.41, p
<0.0001).
Given the larger percentage of non-detects in the cord blood, we
examined the correlations between maternal As levels and cord blood
levels only for those samples above the LOD and found poor correla-
tions of 0.19 (n=762) with 1st trimester maternal blood, 0.29 with 3rd
trimester maternal blood (n=701) and 0.05 (n=681) with 1st trimester
DMA. While the sensitivity of detectable maternal blood As or urinary
DMA to predict detectable levels in cord blood was very good (96.6%
and 93.5% for 1st and 3rd trimester blood, respectively and 86.5% for
DMA, the speciﬁcity was poor ( <22%) (data not shown).
Table 2 shows how total As in 1st and 3rd trimester blood
(combined) varied by maternal characteristics. Signiﬁcantly higher
maternal blood As concentrations were observed in women who were
older, foreign-born, nulliparous, former or never smokers, university
educated, and blood sample collection in spring (compared to the fall).
A further analysis of country of birth revealed signiﬁcant diﬀerences
between Canadian women and women born in Asia and Europe
(Table 3). In addition, women who identiﬁed as Asian (Chinese, south
Table 1
Descriptive statistics for total arsenic in maternal blood (µg/L), umbilical cord blood (µg/L), and meconium (µg/g).
Kaplan-Meier Maximum-Likelihood 95th
Sample Type N LOD %<LOD Min Median 95% CIa GM 95% CIb Percentile Max
1st trimester blood 1938 0.225 7.5 <LOD 0.82 0.79 0.86 0.75 0.73 0.78 2.32 34.46
3rd trimester blood 1673 0.225 12.7 <LOD 0.69 0.65 0.73 0.67 0.64 0.69 2.77 32.96
Umbilical cord blood 1416 0.599c 50.9 <LOD NA NA NA NA NA NA 2.55 17.98
Meconium 1591 0.02 93.9 <LOD NA NA NA NA NA NA 0.02 0.55
LOD: Limit of detection
GM: Geometric mean
NA: Indicates that the estimate is ‘not applicable’ due to a high level of censoring
a 95% Conﬁdence Intervals (CI) computed using Greenwood's estimate of the standard error.
b 95% CI computed using the Maximum likelihood method.
c Upper limit of detection; cord blood LODs ranged from 0.225 to 0.599 depending on sample dilution prior to instrument analysis.
Table 2
Differences in total arsenic (µg/L) in 1st and 3rd trimester blood by maternal characteristics.
Characteristic Group Variable Na GMb 95% CIc Diﬀerencesd p-value
Age (years) <25 244 0.59 (0.51, 0.69) A 0.0001
25–29 848 0.68 (0.62, 0.73) AB
30–34 1290 0.71 (0.67, 0.76) BC
≥35 1229 0.77 (0.72, 0.82) C
Parity 0 1604 0.74 (0.70, 0.79) A 0.005
1 1447 0.71 (0.67, 0.75) AB
≥2 557 0.64 (0.59, 0.71) B
Pre-pregnancy BMI Underweight to Normal (BMI <25) 2141 0.73 (0.70, 0.76) 0.1
Overweight (25≤BMI <30) 720 0.71 (0.65, 0.77)
Obese (BMI≥30) 487 0.66 (0.60, 0.73)
Canadian-born No 677 0.84 (0.79, 0.90) A 0.0001
Yes 2934 0.69 (0.66, 0.71) B
Smoking status Current 427 0.63 (0.56, 0.70) A 0.002
Former 974 0.75 (0.70, 0.81) B
Never 2205 0.71 (0.68, 0.75) B
Household income ≤$50,000 618 0.69 (0.63, 0.75) 0.42
$50,001–$100,000 1433 0.71 (0.67, 0.76)
>$100,000 1398 0.73 (0.68, 0.77)
Education High school or less 309 0.6 (0.53, 0.68) A <0.0001
Some college 1031 0.68 (0.63, 0.72) A
Undergraduate degree or higher 2267 0.75 (0.71, 0.78) B
Season Fall 995 0.68 (0.64, 0.73) A 0.006
Winter 826 0.74 (0.69, 0.79) AB
Spring 947 0.75 (0.70, 0.80) B
Summer 843 0.69 (0.65, 0.74) AB
Fasting status No 3532 0.71 (0.69, 0.73) 0.30
Yes 69 0.78 (0.66, 0.93)
a 1st and 3rd trimesters combined.
b Geometric means calculated using both 1st and 3rd trimester measurements.
c Conﬁdence Intervals (CI) are corrected for multiple pairwise comparisons (Bonferroni-adjusted).
d Results of statistical hypothesis testing of diﬀerences by maternal group characteristics: letters shared in common between the groups indicate no signiﬁcant diﬀerence, whereas
groups that do not share a letter are signiﬁcantly diﬀerent from each other.
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Asian, Filipino, southeast Asian, Japanese, Korean), had a signiﬁcantly
higher blood As level (GM 0.913 µg/L) compared to non-Asian women
(GM 0.701 µg/L). No signiﬁcant diﬀerences were observed by pre-
pregnancy BMI, household income, or fasting status.
Table 4 shows descriptive statistics for species of inorganic and
organic arsenic in 1st trimester urine, both unadjusted and adjusted for
speciﬁc gravity. Due to the high percentage of values below the limit of
detection ( >50%) for species other than DMA, estimates for the
median and geometric mean were not applicable in most cases. DMA
ranged from <LOD to 64.42 (95th percentile: 11.99) µg As/L and
<LOD to 44.14 (95th percentile: 9.74) µg As/L when unadjusted and
adjusted for speciﬁc gravity, respectively.
There was a weak but signiﬁcant linear correlation between total
arsenic in blood and speciﬁc gravity-adjusted DMA in urine (Spearman
r=0.33, p <0.0001). Correlations were not calculated for the other
urinary arsenic species with total blood arsenic since more than 50% of
the samples were less than LOD for As-III, As-V, MMA and AsB.
Table 5 shows diﬀerences in dimethylarsinic acid (DMA) in 1st
trimester urine by maternal characteristics when speciﬁc gravity is
modeled as a linear covariate. Similar to what was observed for the
blood measures, signiﬁcant diﬀerences were observed for age, parity,
country of birth, smoking, and education. In addition, lower maternal
DMA concentrations were observed in women with pre-pregnancy BMI
≥30. There were no signiﬁcant diﬀerences with fasting status or time
since last urination.
4. Discussion
Among a large, geographically diverse sample of pregnant women
across ten sites in Canada, arsenic was frequently detected in maternal
blood (92.5% and 87.3%, respectively in 1st and 3rd trimesters), while
urinary arsenic species were less commonly detected. Arsenic species in
1st trimester urine were <LOD for most samples except for DMA
which was above the LOD for over 85% of samples. This is consistent
with concurrent data from females aged 20–39 years in the Canadian
Health Measures Survey (CHMS)(Cycle 2: 2009–2011) which found
urine levels <LOD for As3+(76.06% <LOD), As5+(100% <LOD), MMA
(77.66% <LOD), and AsB (41.49% <LOD) (Health Canada, 2013). In
the CHMS, DMA was detected in almost 94% of samples with a
geometric mean (95% CI) of 3.5 (2.6–4.7) µg/L compared to greater
than 85% detection in our cohort with a geometric mean of 2.3 (2.2–
2.4) µg/L, not adjusted for speciﬁc gravity. Similarly, the inorganic
arsenic species were mostly undetected in urine in the US NHANES
2009–2010 analysis, with similar detection limits (CDC, 2015).
While the percentages of women with detectable blood arsenic in a
national survey and in MIREC were similar, Canadian women of
reproductive age (20–39 years) from 2007 to 2009 had a geometric
mean (GM) of 0.88 µg/L and 95th percentile of 4.0 µg/L (Health
Canada, 2010), compared to a GM of 0.75 µg/L and 95th percentile of
2.32 µg/L in MIREC 1st trimester blood. Among infants born to these
women, greater than 50% and 93% of samples, respectively, were
<LOD for total arsenic in umbilical cord blood and meconium. An
analytical method with a lower detection limit in meconium would have
yielded more precise data for those samples <LOD, as arsenic has been
measured in meconium in studies with lower detection limits in Japan
(median 0.03 ppb) (Yang et al., 2013), Taiwan (GM 33 µg/kg) (Jiang
et al., 2014) and China (median 37.78 ng/g) (Peng et al., 2015).
In general, urinary arsenic has been the more common biomarker
of exposure for the measurement of total arsenic or speciated metabo-
lites used in epidemiologic studies possibly due to the non-invasive
mode of sample collection. However, as discussed in detail below, the
lack of consistent methods may limit interpretability and comparisons
across studies. We note below that blood arsenic has been more
Table 3
Maternal blood arsenic levelsa by region of birth.
Region N GMb (95%
CI)c
Diﬀerencesd p-value
Africa 55 0.82 (0.56,
1.20)
AB <0.0001
Asia 125 1.10 (0.85,
1.41)
A
Caribbean 59 0.92 (0.63,
1.33)
AB
Central or South
America
83 0.71 (0.52,
0.97)
AB
Eastern Europe 75 0.64 (0.46,
0.89)
AB
Europe 168 0.96 (0.77,
1.19)
A
Middle East 48 0.60 (0.40,
0.90)
AB
US and Oceania 64 0.80 (0.56,
1.14)
AB
Canada 2934 0.69 (0.65,
0.72)
B
a 1st and 3rd trimester measurements combined.
b Geometric means calculated using both 1st and 3rd trimester measurements.
c Conﬁdence Intervals (CI) are corrected for multiple pairwise comparisons
(Bonferroni-adjusted).
d Results of statistical hypothesis testing of diﬀerences by maternal group character-
istics: letters shared in common between the groups indicate no signiﬁcant diﬀerence,
whereas groups that do not share a letter are signiﬁcantly diﬀerent from each other.
Table 4
Descriptive statistics for speciated arsenic (µg As/L) in 1st trimester urine, unadjusted and adjusted for specific gravity.
Kaplan-Meier Maximum-Likelihood 95th
Arsenic Species N LOD % <LOD Min Median 95% Cla GM 95% CIb Percentile Max
Arsenous acid (As-III) 1933 0.75 84.1 <LOD NA NA NA NA NA NA 1.95 23.97
As-III adjustedc <LOD NA NA NA NA NA NA 3.25 24.10
Arsenic acid (As-V) 1933 0.75 98.5 <LOD NA NA NA NA NA NA NA 22.47
As-V adjustedc <LOD NA NA NA NA NA NA NA 15.58
Monomethylarsonic acid (MMA) 1933 0.75 92.5 <LOD NA NA NA NA NA NA 0.82 11.24
MMA adjustedc <LOD NA NA NA NA NA NA 3.25 9.74
Dimethylarsinic acid (DMA) 1933 0.75 14.1 <LOD 2.40 2.26 2.53 2.30 2.20 2.41 11.99 64.42
DMA adjustedc <LOD 2.39 2.30 2.47 2.57 2.49 2.65 9.74 44.14
Arsenobetaine (AsB) 1933 0.75 51.2 <LOD NA NA NA NA NA 0.81 29.51 1573.03
AsB adjustedc <LOD 0.77 NA 0.89 0.79 NA 0.89 33.79 889.11
LOD: Limit of detection.
NA: Indicates that the estimate is ‘not applicable’ due to a high level of censoring.
a Conﬁdence Intervals (CI) computed using Greenwood's estimate of the standard error.
b Conﬁdence Intervals (CI) computed using the Maximum likelihood method.
c Adjusted for urine speciﬁc gravity.
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commonly used in studies conducted among pregnant women and their
infants possibly because these subjects are already undergoing blood
collection as part of their clinical care. While arsenic in blood is cleared
within several hours of being absorbed, it may reach a steady state
following chronic exposure (Hall et al., 2006; Hughes, 2006).
Maternal total blood arsenic, representing the sum of both inor-
ganic and organic exposure, in the MIREC cohort ranged from <LOD
to 34.5 (median 0.8) and 33.0 (median 0.7) µg/L, respectively, in the
1st and 3rd trimesters of pregnancy. These results are consistent with a
birth cohort study carried out near the Tar Creek Superfund site in
Oklahoma (USA) where total blood arsenic at delivery in 532 women
ranged from <LOD to 24.1 (median 1.4) µg/L (Ettinger et al., 2009). A
2010 study in Shanxi, China that measured total blood arsenic using
less sensitive atomic ﬂuorescence spectrophotometry (AFS) among 212
women in the 1st and 2nd trimesters of pregnancy observed much
lower levels ranging from 0.04 to 2.2 (median 0.5) µg/L (Jin et al.,
2014). Levels in that study were signiﬁcantly higher than the median
among those with reported consumption of pork, meat, or mutton
(24% higher) and use of coal as a cooking fuel (36% higher). We noted
signiﬁcantly higher As levels in Asians, similar to what has been
reported in the U.S. NHANES 2011–2012 data (Awata et al., 2016a)
where Asians had the highest daily ﬁsh and rice consumption across
the racial/ethnic groups, with ﬁsh being the major contributor to total
arsenic intake, while rice was the major contributor to inorganic
arsenic dietary intake (Awata et al., 2016b).
In a study among women from the Salta province of Argentina, total
blood arsenic ranged from 5.6 to 13 (median 11) µg/L in late (average
39 weeks) gestation (Concha et al., 1998). Arsenic in umbilical cord
blood was similar (range 6–12, median 9 µg/L) to that in maternal
blood with a signiﬁcant correlation between the two measures,
suggesting that arsenic was transferred to the fetus. We also found
detectable arsenic in about 50% of umbilical cord blood samples at
birth (range <LOD to 18 µg/L). Among those cord bloods with
detectable As in our study, the correlation with the corresponding
maternal blood As was poor; however the sensitivity of detectable As in
maternal blood to predict detectable As in cord blood was very good,
Table 5
Differences in dimethylarsinic acid (µg As/L) in 1st trimester urine by maternal characteristics with specific gravity modeled as a linear covariate.
Characteristic Group Variable N %<LOD GM 95% CIa Diﬀerencesb p-value
Age (years) <25 132 14.4 1.76 (1.49, 2.09) A <0.0001
25–29 448 14.5 2.18 (1.99, 2.39) AB
30–34 693 15.0 2.38 (2.21, 2.56) B
≥35 660 12.9 2.45 (2.28, 2.64) B
Parity 0 853 12.3 2.54 (2.39, 2.70) A <0.0001
1 780 15.6 2.15 (2.02, 2.29) B
2+ 298 15.4 2.09 (1.89, 2.31) B
Pre-pregnancy BMI BMI <25 1136 14.0 2.44 (2.32, 2.57) A <0.0001
25≤BMI <30 392 14.3 2.24 (2.05, 2.44) AB
BMI≥30 265 14.7 1.89 (1.69, 2.11) B
Canadian-born No 363 9.6 3.14 (2.92, 3.37) A <0.0001
Yes 1570 15.2 2.15 (2.08, 2.23) B
Smoking status Current 229 13.5 2.00 (1.78, 2.24) A 0.006
Former 530 14.5 2.32 (2.15, 2.51) AB
Never 1172 14.1 2.37 (2.25, 2.49) B
Household income ≤$50,000 336 11.6 2.16 (1.96, 2.38) A 0.004
$50,001–$100,000 767 14.9 2.25 (2.11, 2.39) A
>$100,000 739 14.1 2.48 (2.33, 2.65) A
Education High school or less 173 12.7 1.96 (1.71, 2.24) A <0.0001
Some college 555 16.8 2.00 (1.85, 2.15) A
Undergraduate degree or higher 1203 13.1 2.52 (2.40, 2.65) B
Season Fall 563 17.6 2.14 (1.97, 2.32) A 0.012
Winter 470 12.6 2.31 (2.11, 2.53) A
Spring 447 13.4 2.48 (2.27, 2.72) A
Summer 453 12.1 2.35 (2.15, 2.58) A
Fasting status No 1868 14.4 2.30 (2.23, 2.38) 0.64
Yes 39 10.3 2.18 (1.73, 2.74)
Time of urine sample collection 6:00–9:00 28 17.9 4.62c (2.94, 7.26) 0.15
9:00–12:00 827 17.1 4.93c (4.57, 5.32)
12:00–15:00 659 12.9 4.57c (4.23, 4.93)
15:00–18:00 379 10.3 4.73c (4.27, 5.25)
18:00–24:00 38 7.9 4.04c (2.90, 5.61)
Time since last urination (minutes) ≤75 504 18.9 2.17 (1.99, 2.37) 0.26
76–120 607 12.9 2.35 (2.17, 2.54)
121–170 272 16.5 2.38 (2.12, 2.68)
>170 453 9.5 2.31 (2.11, 2.53)
a Conﬁdence Intervals (CI) are corrected for multiple pairwise comparisons (Bonferroni-adjusted).
b Results of statistical hypothesis testing of diﬀerences by maternal group characteristics: letters shared in common between the groups indicate no signiﬁcant diﬀerence, whereas
groups that do not share a letter are signiﬁcantly diﬀerent from each other.
c Speciﬁc gravity-adjusted GM, as a signiﬁcant interaction was observed between SG as a covariate and time of sample collection.
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supporting the notion of some fetal transfer.
In the Argentinian study, essentially all of the arsenic in the blood
and urine of mothers in late gestation (as well as in newborn blood)
was in the form of DMA which may indicate that arsenic methylation is
increased during pregnancy (Concha et al., 1998). Interestingly, the
increased methylation in late gestation was associated with lower
arsenic concentrations in blood and higher concentrations in urine,
compared with a few months postpartum, suggesting that methylation
may be inhibited at higher exposure levels (Vahter, 2009). Arsenic
methylation eﬃciency varies between individuals, as well as within
individuals over time (Kile et al., 2009). In general, those with higher
ratios of MMA to DMA in urine or blood are thought to be less eﬃcient
methylators and may be at greater risk for arsenic-related health eﬀects
(National Research Council (NRC), 2013). Women of childbearing age
have been shown to be more eﬃcient arsenic methylators than men
and, among populations with relatively low exposure, methylation
eﬃciency appears to increase across pregnancy (Gardner et al., 2011).
Laine et al. (2015) found negative associations between %MMA in
maternal third trimester urine and birth weight and placental weight in
a Mexican birth cohort where approximately half the mothers had
elevated ( >10 µg/L) drinking water arsenic. A recent meta-analysis of
16 studies, including several prospective birth cohort studies, revealed
small but statistically signiﬁcant increased risks of spontaneous abor-
tion, stillbirth, and neonatal and infant mortality among populations
highly-exposed to arsenic in drinking water; however, when the
analysis was restricted to the seven highest quality studies, statistical
signiﬁcance was only achieved for infant mortality (Quansah et al.,
2015). Inorganic arsenic in drinking water has been associated with
adverse birth outcomes at relatively low levels of exposure (Bloom
et al., 2014).
It has been suggested in highly-exposed populations such as
Bangladesh that the immunosuppressive eﬀects of prenatal As expo-
sure (Ahmed et al., 2011, 2014) may increase the risk of infant
morbidity and mortality from infectious diseases (Rahman et al.,
2011). In a New Hampshire (USA) birth cohort with lower drinking
water As exposure than the aforementioned Bangladesh studies,
researchers also found increased risk of diarrhea and respiratory
infections (Farzan et al., 2013) and altered immune cell and gene
expression in cord blood (Nadeau et al., 2014) among infants of
mothers with higher inorganic arsenic exposures in that population.
It is recognized that a host of biological and behavioral factors
modify biomarkers of arsenic exposure and may be responsible for
inter-individual diﬀerences in arsenic metabolism (Calderon et al.,
2013; Hudgens et al., 2016). In addition to the state of pregnancy itself,
it may be that underlying genetic susceptibility factors are responsible
for diﬀerences in arsenic metabolism and toxicity. Arsenic methyl-
transferase (AS3MT) genotype has been shown to inﬂuence the arsenic
methylation proﬁle phenotype (Gardner et al., 2012; Engström et al.,
2013). Other genetic and epigenetic mechanisms may also be respon-
sible (Bailey and Fry, 2014). Although the inﬂuence of changes to
arsenic methylation during pregnancy on child health outcomes is not
well understood, it is clear that a better understanding of the eﬀects of
prenatal arsenic exposure, including factors associated with such
exposure, is needed.
We also measured speciated arsenic in urine and found diﬀerences
by maternal characteristics in the detected urinary arsenic species,
namely DMA, both when unadjusted and adjusted for speciﬁc gravity.
In general, higher levels were observed in women who were older,
foreign-born, and had higher education. This may be due to diﬀerences
in diet, such as consumption of green tea (Colapinto et al., 2016),
seafood, fruit, grains, milk or rice consumption, which are known to
inﬂuence arsenic exposure (DeCastro et al., 2014). Comparison of
urinary arsenic levels, including examination of sources of exposure,
across studies is limited by the lack of consistent methods for
laboratory and statistical analysis and presentation.
Some studies have used creatinine to control for urinary dilution,
but it is now recognized that urinary creatinine is aﬀected by age, sex,
body size, and diet, particularly protein intake, and adjustment by
creatinine may provide higher values for urinary arsenic concentrations
than speciﬁc gravity (Nermell et al., 2008). Urinary creatinine may also
be aﬀected by several disease processes; for example, among diabetics
adjustment for creatinine has been found to overestimate arsenic
concentrations (Yassine et al., 2012). We found that speciﬁc gravity
was a highly signiﬁcant covariate, indicating its importance to the
analysis of urinary arsenic species. Additionally, modeling speciﬁc
gravity as a covariate allows the urinary analyte concentration to be
appropriately adjusted for urine dilution and the statistical signiﬁcance
of other variables in the model to be evaluated independently from the
eﬀects of speciﬁc gravity. It also provides additional model ﬂexibility
due to the ability to evaluate interaction terms in multiple regression
analysis.
In summary, among this population of pregnant woman and
newborns, levels of arsenic measured in blood and urine were lower
than national population ﬁgures for women of reproductive age (20–39
years) in Canada. Further research is needed to elucidate sources of
exposure and factors that may inﬂuence arsenic exposure in pregnant
women and children. Future studies should take care to present results
in a detailed and consistent manner to allow for comparisons over time
and across populations.
Funding
The MIREC study was supported by Health Canada's Chemicals
Management Plan, the Canadian Institute of Health Research (grant #
MOP-81285) and the Ontario Ministry of the Environment.
Human subjects' ethics review
The study was reviewed and approved by the Research Ethics Board
of Health Canada as well as the ethics committees at each of the 10
participating clinical study sites and collaborating institutions.
Acknowledgements
The authors would like to thank: Dr. Ruth Nysen for providing SAS
macros to compute the left-censored test for log-normality based on the
paper by Nysen et al. (2012); Byron Cotnam for statistical support; and
Dr. Anne Riederer for assistance with the literature review and
summary. The dedication of the MIREC participants, coordinating
and recruitment site staﬀ, and the site investigators is gratefully
acknowledged. The MIREC study was funded by Health Canada's
Chemicals Management Plan, the Canadian Institute of Health
Research (grant # MOP-81285) and the Ontario Ministry of the
Environment.
References
Abhyankar, L.N., Jones, M.R., Guallar, E., Navas-Acien, A., 2012. Arsenic exposure and
hypertension: a systematic review. Environ. Health Perspect. 120 (4), 494–500.
http://dx.doi.org/10.1289/ehp.1103988.
Ahmed, S., Mahabbat-e Khoda, S., Rekha, R.S., Gardner, R.M., Ameer, S.S., Moore, S.,
Ekström, E.C., Vahter, M., Raqib, R., 2011. Arsenic-associated oxidative stress,
inﬂammation, and immune disruption in human placenta and cord blood. Environ.
Health Perspect. 119 (2), 258–264. http://dx.doi.org/10.1289/ehp.1002086.
Ahmed, S., Moore, S.E., Kippler, M., Gardner, R., Hawlader, M.D., Wagatsuma, Y.,
Raqib, R., Vahter, M., 2014. Arsenic exposure and cell-mediated immunity in pre-
school children in rural bangladesh. Toxicol. Sci. 141 (1), 166–175. http://
dx.doi.org/10.1093/toxsci/kfu113.
Arbuckle, T.E., Fraser, W.D., Fisher, M., Davis, K., Liang, C.L., Lupien, N., Bastien, S.,
Velez, M.P., von Dadelszen, P., Hemmings, D.G., Wang, J., Helewa, M., Taback, S.,
Sermer, M., Foster, W., Ross, G., Fredette, P., Smith, G., Walker, M., Shear, R.,
Dodds, L., Ettinger, A.S., Weber, J.P., D'Amour, M., Legrand, M., Kumarathasan, P.,
Vincent, R., Luo, Z.C., Platt, R.W., Mitchell, G., Hidiroglou, N., Cockell, K.,
Villeneuve, M., Rawn, D.F., Dabeka, R., Cao, X.L., Becalski, A., Ratnayake, N.,
Bondy, G., Jin, X., Wang, Z., Tittlemier, S., Julien, P., Avard, D., Weiler, H., Leblanc,
A., Muckle, G., Boivin, M., Dionne, G., Ayotte, P., Lanphear, B., Séguin, J.R., Saint-
A.S. Ettinger et al. Environmental Research 153 (2017) 8–16
14
Amour, D., Dewailly, E., Monnier, P., Koren, G., Ouellet, E., 2013. Cohort proﬁle: the
maternal-infant research on environmental chemicals research platform. Paediatr.
Perinat. Epidemiol. 27 (4), 415–425.
Ashley-Martin, J., Dodds, L., Arbuckle, T.E., Ettinger, A.S., Shapiro, G.D., Fisher, M.,
Taback, S., Bouchard, M.F., Monnier, P., Dallaire, R., Fraser, W.D., 2015a. Maternal
blood metal levels and fetal markers of metabolic function. Environ. Res. 136, 27–34
. http://dx.doi.org/10.1016/j.envres.2014.10.024, (Epub 2014 Nov 20).
Ashley-Martin, J., Levy, A.R., Arbuckle, T.E., Platt, R.W., Marshall, J.S., Dodds, L.,
2015b. Maternal exposure to metals and persistent pollutants and cord blood
immune system biomarkers. Environ. Health 14, 52. http://dx.doi.org/10.1186/
s12940-015-0046-3.
Awata, H., Linder, S., Mitchell, L.E., Delclos, G.L., 2016a. Biomarker levels of toxic
metals among Asian populations in the U.S.: NHANES 2011–2012. Environ. Health
Perspect., [Epub ahead of print].
Awata, H., Linder, S., Mitchell, L.E., Delclos, G.L., 2016b. Association of dietary intake
and biomarker levels of arsenic, cadmium, lead, and mercury among Asian
populations in the U.S.: NHANES 2011–2012. Environ. Health Perspect., [Epub
ahead of print].
Bailey, K., Fry, R.C., 2014. Long-term health consequences of prenatal arsenic exposure:
links to the genome and the epigenome. Rev. Environ. Health 29 (1–2), 9–12.
http://dx.doi.org/10.1515/reveh-2014-0006.
Bélanger, P., Dumas, P., 2010. Fast determination of urine arsenic species by ion
exchange chromatography and HPLC-ICP-MS using collision-reactive interface. At.
Spectrosc. 31 (6), 175–181.
Bloom, M.S., Surdu, S., Neamtiu, I.A., Gurzau, E.S., 2014. Maternal arsenic exposure and
birth outcomes: a comprehensive review of the epidemiologic literature focused on
drinking water. Int. J. Hyg. Environ. Health 217 (7), 709–719. http://dx.doi.org/
10.1016/j.ijheh.2014.03.004.
Calderon, R.L., Hudgens, E.E., Carty, C., He, B., Le, X.C., Rogers, J., Thomas, D.J., 2013.
Biological and behavioral factors modify biomarkers of arsenic exposure in a U.S.
population. Environ. Res. 126, 134–144. http://dx.doi.org/10.1016/
j.envres.2013.04.004.
CDC, 2015. Fourth National Report on Human Exposure to Environmental Chemicals.
〈http://www.cdc.gov/biomonitoring/pdf/FourthReport_UpdatedTables_Feb2015.
pdf〉.( accessed 15.07.16).
Colapinto, C.K., Arbuckle, T.E., Dubois, L., Fraser, W., 2016. Is there a relationship
between tea intake and maternal whole blood heavy metal concentrations? J. Expo.
Sci. Environ. Epidemiol.. http://dx.doi.org/10.1038/jes.2015.86, (Epub ahead of
print).
Cohen, S.M., Arnold, L.L., Eldan, M., Lewis, A.S., Beck, B.D., 2006. Methylated
arsenicals: the implications of metabolism and carcinogenicity studies in rodents to
human risk assessment. Crit. Rev. Toxicol. 36 (2), 99–133.
Concha, G., Vogler, G., Lezcano, D., Nermell, B., Vahter, M., 1998. Exposure to inorganic
arsenic metabolites during early human development. Toxicol. Sci. 44 (2), 185–190.
deCastro, B.R., Caldwell, K.L., Jones, R.L., Blount, B.C., Pan, Y., Ward, C., Mortensen,
M.E., 2014. Dietary sources of methylated arsenic species in urine of the United
States population, NHANES 2003–2010. PLoS One 9 (9), e108098. http://
dx.doi.org/10.1371/journal.pone.0108098.
Engström, K.S., Hossain, M.B., Lauss, M., Ahmed, S., Raqib, R., Vahter, M., Broberg, K.,
2013. Eﬃcient arsenic metabolism–the AS3MT haplotype is associated with DNA
methylation and expression of multiple genes around AS3MT. PLoS One 8 (1),
e53732. http://dx.doi.org/10.1371/journal.pone.0053732.
Ettinger, A.S., Zota, A.R., Amarasiriwardena, C.J., Hopkins, M.R., Schwartz, J., Hu, H.,
Wright, R.O., 2009. Maternal arsenic exposure and impaired glucose tolerance
during pregnancy. Environ. Health Perspect. 117 (7), 1059–1064. http://dx.doi.org/
10.1289/ehp0800533.
Farzan, S.F., Korrick, S., Li, Z., Enelow, R., Gandolﬁ, A.J., Madan, J., Nadeau, K.,
Karagas, M.R., 2013. In utero arsenic exposure and infant infection in a United
States cohort: a prospective study. Environ. Res. 126, 24–30. http://dx.doi.org/
10.1016/j.envres.2013.05.001.
Gardner, R.M., Nermell, B., Kippler, M., Grandér, M., Li, L., Ekström, E.C., Rahman, A.,
Lönnerdal, B., Hoque, A.M., Vahter, M., 2011. Arsenic methylation eﬃciency
increases during the ﬁrst trimester of pregnancy independent of folate status.
Reprod. Toxicol. 31 (2), 210–218. http://dx.doi.org/10.1016/
j.reprotox.2010.11.002.
Gardner, R.M., Engström, K., Bottai, M., Hoque, W.A., Raqib, R., Broberg, K., Vahter, M.,
2012. Pregnancy and the methyltransferase genotype independently inﬂuence the
arsenic methylation phenotype. Pharmacogenetics Genom. 22 (7), 508–516. http://
dx.doi.org/10.1097/FPC.0b013e3283535d6a.
Hall, M., Chen, Y., Ahsan, H., Slavkovich, V., van Geen, A., Parvez, F., Graziano, J., 2006.
Blood arsenic as a biomarker of arsenic exposure: results from a prospective study.
Toxicology 225 (2–3), 225–233.
Health Canada, 2010. Report on Human Biomonitoring of Environmental Chemicals in
Canada: Results of the Canadian Health Measures Survey Cycle 1 (2007–2009).
August. 〈http://www.hc-sc.gc.ca/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/
contaminants/chms-ecms/report-rapport-eng.pdf〉
Health Canada, 2013. Second Report on Human Biomonitoring of Environmental
Chemicals in Canada: Results of the Canadian Health Measures Survey Cycle 2
(2009–2011). April. HC Pub.: 130019; Cat.: H128-1/10-601-1E-PDF; ISBN: 978-1-
100-22140-3.
Helsel, D.R., 2012. Statistics for Censored Environmental Data Using Minitab and R 2nd
ed.. John Wiley & Sons, Hoboken.
Hudgens, E.E., Drobna, Z., He, B., Le, X.C., Styblo, M., Rogers, J., Thomas, D.J., 2016.
Biological and behavioral factors modify urinary arsenic metabolic proﬁles in a U.S.
population. Environ. Health 15 (1), 62. http://dx.doi.org/10.1186/s12940-016-
0144-x.
Hughes, M.F., 2006. Biomarkers of exposure: a case study with inorganic arsenic.
Environ. Health Perspect. 114 (11), 1790–1796.
IARC (International Agency for Research on Cancer), 2012. A Review of Human
Carcinogens: Arsenic, Metals, Fibres, and Dusts. IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans 100C. World Health Organization,
Lyon, France, (online) Available:〈http://monographs.iarc.fr/ENG/Monographs/
vol100C/mono100C-6.pdf〉.
Jiang, C.B., Hsi, H.C., Fan, C.H., Chien, L.C., 2014. Fetal exposure to environmental
neurotoxins in Taiwan. PLoS One 9 (10), e109984. http://dx.doi.org/10.1371/
journal.pone.0109984. eCollection.
Jin, Y., Hein, M.J., Deddens, J.A., Hines, C.J., 2011. Analysis of lognormally distributed
exposure data with repeated measures and values below the limit of detection using
SAS. Ann. Occup. Hyg. 55 (1), 97–112. http://dx.doi.org/10.1093/annhyg/meq061.
Jin, L., Liu, J., Ye, B., Ren, A., 2014. Concentrations of selected heavy metals in maternal
blood and associated factors in rural areas in Shanxi Province, China. Environ. Int.
66, 157–164. http://dx.doi.org/10.1016/j.envint.2014.01.016.
Just, A.C., Adibi, J.J., Rundle, A.G., Calafat, A.M., Camann, D.E., Hauser, R., Silva, M.J.,
Whyatt, R.M., 2010. Urinary and air phthalate concentrations and self-reported use
of personal care products among minority pregnant women in New York city. J.
Expo. Sci. Environ. Epidemiol. 20 (7), 625–633. http://dx.doi.org/10.1038/
jes.2010.13.
Kile, M.L., Hoﬀman, E., Hsueh, Y.M., Afroz, S., Quamruzzaman, Q., Rahman, M.,
Mahiuddin, G., Ryan, L., Christiani, D.C., 2009. Variability in biomarkers of arsenic
exposure and metabolism in adults over time. Environ. Health Perspect. 117 (3),
455–460. http://dx.doi.org/10.1289/ehp.11251.
Laine, J.E., Bailey, K.A., Rubio-Andrade, M., Olshan, A.F., Smeester, L., Drobná, Z.,
Herring, A.H., Stýblo, M., García-Vargas, G.G., Fry, R.C., 2015. Maternal arsenic
exposure, arsenic methylation eﬃciency, and birth outcomes in the Biomarkers of
Exposure to ARsenic (BEAR) pregnancy cohort in Mexico. Environ. Health Perspect.
123 (2), 186–192. http://dx.doi.org/10.1289/ehp.1307476.
Le, X.C., Lu, X., Ma, M., Cullen, W.R., Aposhian, H.V., Zheng, B., 2000. Speciation of key
arsenic metabolic intermediates in human urine. Anal. Chem. 72, 5172–5177.
Lovreglio, P., D'Errico, M.N., Gilberti, M.E., Drago, I., Basso, A., Apostoli, P., Soleo, L.,
2012. The inﬂuence of diet on intra and inter-individual variability of urinary
excretion of arsenic species in Italian healthy individuals. Chemosphere 86 (9),
898–905. http://dx.doi.org/10.1016/j.chemosphere.2011.10.050, (Epub 2011 Nov
21).
McCulloch, C.E., Searle, S.R., Neuhaus, J.M., 2008. Generalized, Linear and Mixed
Models 2nd ed.. John Wiley and Sons.
Molin M., Ulven S., Meltzer H., Alexander J., 2015. Arsenic in the human food chain,
biotransformation and toxicology - Review focusing on seafood arsenic. J Trace Elem
Med Biol Jan 28. pii: S0946-672X(15)00012-7.
Nadeau, K.C., Li, Z., Farzan, S., Koestler, D., Robbins, D., Fei, D.L., Malipatlolla, M.,
Maecker, H., Enelow, R., Korrick, S., Karagas, M.R., 2014. In utero arsenic exposure
and fetal immune repertoire in a US pregnancy cohort. Clin. Immunol. 155 (2),
188–197. http://dx.doi.org/10.1016/j.clim.2014.09.004.
National Research Council (NRC), 2013. Critical Aspects of EPA's IRIS Assessment of
Inorganic Arsenic: interim Report. National Academies Press, Washington, D.C.
Nermell, B., Lindberg, A.L., Rahman, M., Berglund, M., Persson, L.A., El Arifeen, S.,
Vahter, M., 2008. Urinary arsenic concentration adjustment factors and
malnutrition. Environ. Res. 106 (2), 212–218.
Newcombe, C., Raab, A., Williams, P.N., Deacon, C., Haris, P.I., Meharg, A.A., Feldmann,
J., 2010. Accumulation or production of arsenobetaine in humans? J. Environ.
Monit. 12 (4), 832–837. http://dx.doi.org/10.1039/b921588c, (Epub 2010 Feb 16).
Nysen, R., Aerts, M., Faes, C., 2012. Testing goodness of ﬁt of parametric models for
censored data. Stat. Med. 31, (2374–238).
Peng, S., Liu, L., Zhang, X., Heinrich, J., Zhang, J., Schramm, K.W., Huang, Q., Tian, M.,
Eqani, S.A., Shen, H., 2015. A nested case-control study indicating heavy metal
residues in meconium associate with maternal gestational diabetes mellitus risk.
Environ. Health 14, 19. http://dx.doi.org/10.1186/s12940-015-0004-0.
Quansah, R., Armah, F.A., Essumang, D.K., Luginaah, I., Clarke, E., Marfo, K., Cobbina,
S.J., Nketiah-Amponsah, E., Namujju, P.B., Obiri, S., Dzodzomenyo, M., 2015.
Association of arsenic with adverse pregnancy outcomes-infant mortality: a
systematic review and meta-analysis. Environ. Health Perspect., [Epub ahead of
print]. Available at:)〈http://ehp.niehs.nih.gov/1307894/〉.
Rahman, A., Vahter, M., Ekström, E.C., Persson, L.Å., 2011. Arsenic exposure in
pregnancy increases the risk of lower respiratory tract infection and diarrhea during
infancy in Bangladesh. Environ. Health Perspect. 119 (5), 719–724. http://
dx.doi.org/10.1289/ehp.1002265.
Rivera-Núñez, Z., Meliker, J.R., Meeker, J.D., Slotnick, M.J., Nriagu, J.O., 2012. Urinary
arsenic species, toenail arsenic, and arsenic intake estimates in a Michigan
population with low levels of arsenic in drinking water. J. Expo. Sci. Environ.
Epidemiol. 22 (2), 182–190. http://dx.doi.org/10.1038/jes.2011.27, (Epub 2011
Aug 31).
Selevan, S.G., Kimmel, C.A., Mendola, P., 2000. Identifying critical windows of exposure
for children's health. Environ. Health Perspect. 108 (Suppl 3), 451–455.
Shapiro, G.D., Dodds, L., Arbuckle, T.E., Ashley-Martin, J., Fraser, W., Fisher, M.,
Taback, S., Keely, E., Bouchard, M.F., Monnier, P., Dallaire, R., Morisset, A.,
Ettinger, A.S., 2015. Exposure to phthalates, bisphenol A and metals in pregnancy
and the association with impaired glucose tolerance and gestational diabetes
mellitus: the MIREC study. Environ. Int. 83, 63–71. http://dx.doi.org/10.1016/
j.envint.2015.05.016, (Epub 2015 Jun 20).
Thomas, S., Arbuckle, T.E., Fisher, M., Fraser, W.D., Ettinger, A., King, W., 2015. Metals
exposure and risk of small-for-gestational age birth in a Canadian birth cohort: the
MIREC study. Environ. Res. 140, 430–439. http://dx.doi.org/10.1016/
j.envres.2015.04.018, (Epub 2015 May 15).
A.S. Ettinger et al. Environmental Research 153 (2017) 8–16
15
Tsuji, J.S., Perez, V., Garry, M.R., Alexander, D.D., 2014. Association of low-level arsenic
exposure in drinking water with cardiovascular disease: a systematic review and risk
assessment. Toxicology 323, 78–94.
Vahter, M., 2009. Eﬀects of arsenic on maternal and fetal health. Annu Rev. Nutr. 29,
381–399.
Vahter, M., Concha, G., 2001. Role of metabolism in arsenic toxicity. Pharmacol. Toxicol.
89 (1), 1–5.
Wang, W., Xie, Z., Lin, Y., Zhang, D., 2014. Association of inorganic arsenic exposure
with type 2 diabetes mellitus: a meta-analysis. J. Epidemiol. Community Health 68
(2), 176–184.
Watanabe, T., Hirano, S., 2013. Metabolism of arsenic and its toxicological relevance.
Arch. Toxicol. 87 (6), 969–979.
Xie, R., Johnson, W., Spayd, S., Hall, G.S., Buckley, B., 2006. Arsenic speciation analysis
of human urine using ion exchange chromatography coupled to inductively coupled
plasma mass spectrometry. Anal. Chim. Acta 578 (2), 186–194.
Yang, Y., Nakai, S., Oda, S., Nishino, H., Ishii, M., Yokoyama, H., Matsuki, H., 2013. A
preliminary study on the use of meconium for the assessment of prenatal exposure to
heavy metals in Japan. J. UOEH 35 (2), 129–135.
Yassine, H., Kimzey, M.J., Galligan, M.A., Gandolﬁ, A.J., Stump, C.S., Lau, S.S., 2012.
Adjusting for urinary creatinine overestimates arsenic concentrations in diabetics.
Cardiorenal Med. 2 (1), 26–32.
A.S. Ettinger et al. Environmental Research 153 (2017) 8–16
16
